Dendritic cell preparation and preparation method thereof

Abstract

The present application discloses a novel dendritic cell preparation and a preparation method thereof. The cell preparation comprises PD-L1 negative dendritic cells and/or dendritic cells with CD40 agonists bound to the cell surface. The preparation method comprises: blocking and/or activating dendritic cells with a treatment agent, wherein the treatment agent comprises PD-L1 antibodies and/or CD40 agonists. The specific method includes adding the treatment agent to block and/or activate dendritic cells either during the dendritic cell culture stage or after completion of the culture. The dendritic cell preparation provided by the present application has enhanced maturity, improved antigen presentation, and a superior capacity to activate and amplify antigen-specific T cells compared to conventional dendritic cells, and has broad application prospects in the field of cancer immunotherapy.

Dependencies are inferred from the claim text.